Paper Details

  1. Home
  2. Paper Details

FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.

Author: AbdallahRaëf, AhmadSyed A, AminjonovBotirjon, BoyerEmanuel, ChoiYoo Jin, ClavienPierre-Alain, EshmuminovDilmurodjon, HeJin, HeldUlrike, HeltonScott, HoffeSarah E, JangJin-Young, KatzMatthew H G, KimHongbeom, LehmannKuno, Lopez-LopezVíctor, MagginoLaura, MalinkaThomas, MalleoGiuseppe, MaloneySarah, PalmRussell F, ParkJeong Youp, PatelSameer, PrakashLaura, RangelovaElena, RoseJ Bart, RösslerFabian, SahoraKlaus, SalviaRoberto, SchmockerRyan K, SchneiderMarcel André, ShaibWalid L, TaiebJulien, TimmermannLea, WilsonGregory C, YooChanghoon

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This meta-analysis found that in patients with locally advanced (LAPC) or borderline resectable (BRPC) pancreatic cancer, primary treatment with FOLFIRINOX compared with gemcitabine-based chemotherapy appears to provide a survival benefit for patients that are ultimately unresectable.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Pancreatic cancer often presents as locally advanced (LAPC) or borderline resectable (BRPC). Neoadjuvant systemic therapy is recommended as initial treatment. It is currently unclear what chemotherapy should be preferred for patients with BRPC or LAPC. METHODS: We performed a systematic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250524/

データ提供：米国国立医学図書館（NLM）

Pancreatic Cancer Treatment: A Quest for Optimal Outcomes

This multi-institutional meta-analysis and systematic review explores the effectiveness of two common chemotherapy regimens, FOLFIRINOX and gemcitabine-based therapy, in treating borderline resectable and locally advanced pancreatic cancer. The study examines patient-level data from a large cohort, comparing overall survival rates and resection rates between the two regimens. The authors discovered that FOLFIRINOX provided a survival benefit for patients who were ultimately unresectable, while both regimens yielded similar outcomes for patients who underwent surgical resection.

FOLFIRINOX: A Potential Game-Changer in Pancreatic Cancer Treatment

This meta-analysis suggests that FOLFIRINOX could offer a significant survival advantage for patients with borderline resectable or locally advanced pancreatic cancer who are not surgical candidates. While both regimens performed similarly in resected patients, FOLFIRINOX emerged as a potential treatment option for individuals with a higher risk of unresectability. This research highlights the importance of personalized treatment approaches, selecting the most appropriate regimen based on individual patient factors and disease characteristics.

Navigating Pancreatic Cancer Treatment: Finding the Right Path

Pancreatic cancer presents a formidable challenge, requiring a nuanced approach to treatment. This meta-analysis sheds light on the potential benefits and limitations of two common chemotherapy regimens, providing valuable insights for clinicians and researchers seeking to optimize treatment strategies for patients with this complex disease. The authors underscore the importance of considering individual patient factors and disease characteristics in selecting the most appropriate treatment regimen.

Dr.Camel's Conclusion

This multi-institutional meta-analysis and systematic review examines the effectiveness of FOLFIRINOX and gemcitabine-based chemotherapy in treating borderline resectable and locally advanced pancreatic cancer. The authors discovered that FOLFIRINOX provided a survival benefit for patients who were ultimately unresectable, while both regimens yielded similar outcomes for patients who underwent surgical resection.
Date :
  1. Date Completed 2023-06-12
  2. Date Revised 2023-11-17
Further Info :

Pubmed ID

37020094

DOI: Digital Object Identifier

PMC10250524

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.